Targeted co-delivery of docetaxel and plumbagin via oxidative priming enhances chemoradiotherapy in non-small cell lung cancer Authors: Xueying Bao, Huanhuan Wang, Man Li, Zhuangzhuang Zheng, Xuanzhong Wang, Jianfeng Guo, Xin Jiang Published: 2026 ABSTRACT Docetaxel (DTX)-based concurrent chemoradiotherapy (CCRT) is an important treatment for locally advanced non-small cell lung cancer (NSCLC), but its efficacy is limited by systemic toxicity and radioresistance. Here, we propose an oxidative priming strategy using plumbagin (PLB), a natural redox modulator, to disrupt tumor redox homeostasis and enhance DTX-mediated chemoradiotherapy. PLB markedly sensitized NSCLC cells to DTX, reducing the effective DTX concentration by 33.3-fold in LLC cells and 18-fold in A549 cells. To overcome the pharmacokinetic mismatch between DTX and PLB, we developed a folate receptor-targeted PEGylated liposomal nanoformulation for synchronized co-delivery. This formulation amplified intracellular ROS accumulation to approximately 2.5 times that induced by X-ray alone and 3.3 times that induced by (DTX + PLB)-NP alone, thereby enhancing radiation-induced DNA damage and apoptosis. In vivo, X-ray combined with the targeted nanoformulation achieved a tumor inhibition rate of 99%, while maintaining stable body weight and showing no obvious hematological, hepatic, or renal toxicity. This study provides a redox-guided nanomedicine strategy to enhance DTX-based CCRT for NSCLC at low doses while maintaining favorable preliminary biosafety. Introduction Lung cancer remains the leading cause of cancer-related deaths globally, accounting for approximately 1.8 million fatalities each year. Non-small cell lung cancer (NSCLC) constitutes nearly 85% of all diagnosed lung cancer cases [1,2]. Radiotherapy (RT) plays a crucial role in the treatment of NSCLC, being widely used in both curative and palliative settings throughout the disease's progression [3]. However, intrinsic or acquired radioresistance often leads to local recurrence, and increasing the radiation dose is typically constrained by unacceptable toxicity to surrounding healthy tissues [4,5]. Recent evidence further suggests that tumor cell-intrinsic programs can shape immunosuppressive microenvironmental remodeling, which may further influence therapeutic response [6]. Consequently, concurrent chemoradiotherapy (CCRT) has become the standard approach to overcome radioresistance. Docetaxel (DTX), a potent radiosensitizer in CCRT [7], induces mitotic catastrophe by stabilizing microtubules via β-tubulin binding and triggers NADPH oxidase-mediated ROS production, ultimately leading to apoptosis [8,9]. Despite its therapeutic benefits, the clinical utility of DTX is notably restricted by severe systemic toxicities and tumor cell adaptation mechanisms. Severe systemic toxicities, including neutropenia, significantly narrow its therapeutic window. Tumor cell adaptation and reprogramming further contribute to therapeutic resistance. This adaptive response includes the aberrant activation of pro-survival pathways, such as the PI3K/Akt and NF-κB pathways, along with the upregulation of P-glycoprotein (P-gp) efflux pumps and anti-apoptotic proteins like BCL-2. These molecular escape mechanisms collectively diminish treatment efficacy significantly [[10], [11], [12]]. Hence, novel strategies are urgently needed to enhance the radiosensitizing effect of DTX, mitigate toxicity, and overcome resistance. The biological effects of RT are largely driven by ROS generation via ionizing radiation, which initiates complex cell death pathways through oxidative damage to macromolecules, leading to mechanisms such as apoptosis [13] and ferroptosis [14,15]. However, tumor cells have developed a “redox adaptation” strategy: maintaining high basal ROS levels due to elevated metabolic activity, while establishing a robust antioxidant defense network centered on the Nrf2/KEAP1 axis [16], glutathione (GSH) [17], and the thioredoxin (Trx) system [18]. This network allows tumor cells to withstand external oxidative stress and plays a crucial role in both radioresistance and chemoresistance. A promising therapeutic strategy is to deliberately disrupt this redox balance. Increasing ROS levels beyond the “lethal threshold” of antioxidant capacity can reactivate oxidative cell death pathways [19]. Recent nanomedicine-based studies in other solid tumor models have also shown that amplifying oxidative damage and ferroptosis-related vulnerability can enhance local antitumor efficacy [20]. This approach is expected to significantly enhance NSCLC's sensitivity to RT and DTX, while enabling dose reduction for both modalities, achieving the dual goals of increased efficacy and reduced toxicity [21,22]. Plumbagin (PLB), a natural naphthoquinone derived from Plumbago zeylanica L., has emerged as an attractive redox-active small molecule for oxidative stress-based therapeutic sensitization. Unlike ROS-enhancing strategies that mainly rely on exogenous catalytic ROS production or physical dose enhancement, PLB has been reported to act as a redox cycler that promotes intracellular ROS generation and may interfere with antioxidant buffering systems, including GSH-associated redox defense and detoxifying enzyme activity. In addition, PLB has been shown to modulate multiple survival- and resistance-associated signaling pathways, suggesting its potential to lower the stress tolerance threshold of tumor cells [[23], [24], [25]]. These properties provide a rationale for exploring PLB as an oxidative priming agent to cooperate with DTX-mediated cytotoxicity and radiation-induced oxidative DNA damage. Despite the mechanistic rationale for combining PLB with DTX, their distinct physicochemical properties and pharmacokinetic behaviors limit the stability and in vivo synchronization of the free-drug combination. PEGylated liposomes offer considerable translational potential for improving systemic circulation and tumor delivery. Folate receptor (FR) is frequently overexpressed in NSCLC cells while showing relatively limited expression in many normal tissues, making it an attractive target for tumor-oriented nanodelivery [26,27]. In this study, we developed an FR-targeted PEGylated liposomal formulation to integrate PLB-mediated oxidative priming into NSCLC concurrent chemoradiotherapy. By combining EPR-associated passive accumulation with FA-mediated active targeting, this platform was designed to coordinate the optimized DTX/PLB ratio, tumor accumulation, pharmacokinetic synchronization, and intracellular release. After cellular uptake, PLB acts as an oxidative primer to disrupt redox homeostasis, promote ROS accumulation, impair mitochondrial integrity, shift the BCL-2/BAX balance toward apoptosis, and activate the caspase-3 cascade, thereby lowering the apoptotic threshold of tumor cells. In this pre-sensitized state, co-delivered DTX and X-ray irradiation can more effectively push tumor cells beyond the lethal damage threshold, resulting in enhanced chemoradiotherapeutic efficacy (Fig. 1). Thus, this study provides a low-dose, nanomedicine-enabled CCRT strategy for NSCLC by enabling PLB-induced redox stress to cooperate with both DTX-mediated cytotoxicity and X-ray-induced oxidative DNA damage.Fig. 1Schematic illustration of the “oxidative priming”-driven nanomedicine strategy for potentiating concurrent chemoradiotherapy (CCRT) in NSCLC. Schematic illustration of the “oxidative priming”-driven nanomedicine strategy for potentiating concurrent chemoradiotherapy (CCRT) in NSCLC. Materials and methods Materials DTX was obtained from Aladdin (Shanghai, China). PLB, celastrol (CLT), sanguinarin (SNG), dihydrotanshinone I (DIH), ziyuglycoside II (ZGS II), alantolactone (ALT), oridonin (ORI), and artesunate (ART) (purity ≥98%) were purchased from Tongtian Biotechnology (Shanghai, China). Egg yolk phosphatidylcholine (EPC) was provided by Meilun Biotechnology (Dalian, China). DSPE-PEG2000, DSPE-PEG2000-FA, and cholesterol (Chol) were purchased from Qiyue Biotechnology (Xi'an, China). The Annexin V-FITC/PI apoptosis detection kit was obtained from Yeasen Biotechnology (Shanghai, China). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. Cell culture Human NSCLC A549 cells and murine NSCLC LLC cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin antibiotics. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO2. Animals Male C57BL/6J mice (5-6 weeks old, weighing 18 ± 2 g) were purchased from SPF Biotechnology Co., Ltd. (Beijing, China). All animal procedures were conducted in accordance with the institutional guidelines for the care and use of laboratory animals and were approved by the Animal Ethics Committee of Jilin University. To establish the syngeneic NSCLC model, LLC cells (1 × 106 per mouse) were subcutaneously injected into the right inguinal region of each mouse. Synergism of DTX and PLB in NSCLC cells Cell cytotoxicity was evaluated using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. LLC or A549 cells (5 × 103 cells per well; this seeding density was used for all subsequent 96-well experiments) were seeded in 96-well plates and incubated at 37 °C for 20-24 h. The medium was then replaced with DMEM containing various concentrations of DTX or natural ROS inducers, and cells were incubated for an additional 24 h. After treatment, 20 μL of MTT solution (5 mg/mL) was added to each well containing 180 μL of fresh culture medium, followed by a 4 h incubation. The supernatant was carefully removed, and the resulting formazan crystals were dissolved in dimethyl sulfoxide (DMSO). Absorbance was measured at 570 nm to determine cell viability. To assess the pharmacological interaction between DTX and PLB, LLC or A549 cells were cultured in 96-well plates for 24 h and then treated for 24 h with DTX, PLB, or their combinations at various fixed molar ratios (MR = 1:5, 1:2, 1:1, 2:1, and 5:1). Half-maximal inhibitory concentrations (IC50) were calculated using GraphPad Prism software. Combination index (CI) values were obtained using the Chou-Talalay method via CompuSyn software, where CI < 1, CI = 1, and CI > 1 indicate synergism, additivity, and antagonism, respectively [28]. Molecular docking simulations were performed to investigate the possible intermolecular interactions between PLB and DTX. Docking calculations were performed using AutoDock Vina. Ligand structures were drawn and energy-minimized using ChemDraw and Chem3D. A grid box was defined to cover the potential interaction region between the two molecules, and docking was performed using the default Vina search parameters. The best-ranked binding conformations were selected based on the predicted binding affinity and visualized using PyMOL 2.1 to analyze hydrogen bonding and π-π stacking interactions. To determine whether ROS accumulation functionally contributes to DTX/PLB-induced synergistic cytotoxicity, NAC rescue experiments were performed. LLC and A549 cells were seeded in 96-well plates and cultured for 20–24 h as described above, followed by treatment with NAC, DTX, PLB, DTX + PLB, or DTX + PLB + NAC for 24 h. In the combination groups, DTX and PLB were used at 0.6 μmol/L each for LLC cells and 1.2 μmol/L each for A549 cells, corresponding to total drug concentrations of 1.2 and 2.4 μmol/L, respectively. The single-agent groups received the corresponding concentration of DTX or PLB. Cell viability was then measured using the MTT assay as described above. PLB induces apoptosis in NSCLC cells by promoting the generation of ROS LLC or A549 cells (2 × 105 cells per well) were seeded in 6-well plates and incubated for 24 h. The cells were then treated with PLB at its IC50 concentration (3 μM) for 6, 12, or 24 h. After treatment, cells were stained with the Annexin V-FITC/PI apoptosis detection kit. The percentage of apoptotic cells was quantified by flow cytometry using a BD FACSCalibur system. For protein expression analysis, LLC or A549 cells were seeded at the same density (2 × 105 cells per well) in 6-well plates and treated with PLB (3 μM) for 24 h. Total cellular proteins were extracted using radio immunoprecipitation assay (RIPA) lysis buffer containing phenylmethylsulfonyl fluoride (PMSF), and protein concentrations were determined by the bicinchoninic acid (BCA) assay. Equal amounts of protein (30 μg per sample) were separated by SDS-PAGE at 120 V for 60 to 90 min, followed by transfer onto polyvinylidene difluoride (PVDF) membranes at 200 mA for 90 min. Membranes were blocked with 5% bovine serum albumin (BSA) for 1 h and incubated with primary antibodies (listed in Table S1) at 4 °C overnight. After incubation with appropriate secondary antibodies for 1 h, protein bands were visualized using an enhanced chemiluminescence (ECL) detection reagent and quantified by densitometric analysis using ImageJ software. To measure intracellular ROS levels, cells were seeded in 6-well plates and confocal dishes, followed by treatment with PLB (3 μM) for 6, 12, or 24 h. ROS production was assessed using a DCFH-DA ROS detection kit (Beyotime). Fluorescence signals were analyzed by flow cytometry and imaged by confocal laser scanning microscopy (CLSM, Olympus FV3000). To further confirm PLB-induced ROS generation, cells were co-treated with N-acetylcysteine (NAC) and PLB, and apoptosis was evaluated as described above. To assess mitochondrial membrane potential (MMP), cells were seeded in confocal dishes and subjected to the same treatments. MMP was examined by staining with the JC-1 probe (Yeasen Biotechnology), and fluorescence images were acquired using CLSM. Preparation and characterization of (DTX + PLB)-NP (DTX + PLB)-NP was prepared using a thin-film hydration method. Briefly, DTX (8 mg), PLB (2 mg), EPC (90 mg), Chol (11.5 mg), and DSPE-PEG2000 (12.5 mg) were dissolved in chloroform. After complete dissolution, the organic solvent was removed under reduced pressure at 37 °C using a rotary evaporator, forming a thin lipid film. The film was then hydrated with 0.9% normal saline at 37 °C with gentle shaking at 100 rpm for 2 h. The resulting liposomal suspension was vortexed and sonicated with a probe sonicator in an ice bath for 10 min. The suspension was subsequently extruded through a 0.4 μm polycarbonate membrane for 5 cycles and then through a 0.2 μm polycarbonate membrane for an additional 5 cycles to obtain nanosized liposomes, which were designated as NT-(DTX + PLB)-NP (non-targeted co-loaded liposomes). Unencapsulated drugs were removed by low-speed centrifugation. Following a previously reported method with minor modifications [29], DSPE-PEG2000-FA (2.4 mg) was inserted into NT-(DTX + PLB)-NP using a post-insertion technique. The mixture was incubated at 37 °C with shaking for 1 h to obtain FA-targeted nanoliposomes, which were designated as (DTX + PLB)-NP. Drug-free FA-modified PEGylated liposomes were prepared using the same carrier composition as (DTX + PLB)-NP but without DTX or PLB, and were designated as FA-Blank-NP. Additionally, targeted and non-targeted liposomes loaded with rhodamine or DiD were similarly prepared for imaging experiments. The morphology and particle size of the nanoparticles were examined by transmission electron microscopy (TEM, FEI Tecnai Spirit Biotwin, 120 kV). The hydrodynamic diameter, polydispersity index (PDI), and zeta potential were measured using a Malvern Nano-ZS instrument. The encapsulation efficiency (EE) and drug loading capacity (LC) of DTX and PLB were determined by high-performance liquid chromatography (HPLC, Shimadzu). For DTX, a C18 column was used with UV detection at 227 nm, and the mobile phase consisted of acetonitrile and water at a 60:40 (v/v) ratio. For PLB, UV detection was performed at 260 nm, and the mobile phase consisted of methanol and water containing 0.15% phosphoric acid at a 50:50 (v/v) ratio. The EE was calculated using the formula: (weight of encapsulated drug/total weight of drug added) × 100%, while LC was calculated as (weight of encapsulated drug/total weight of lipids and drugs) × 100%. In vitro drug release was evaluated using a dialysis method. Dialysis bags (MWCO = 2 kDa) containing 5 mL of (DTX + PLB)-NP were dialyzed against 1× PBS containing 1% BSA at pH 5.5, 6.8, or 7.4, and incubated at 37 °C. At predetermined time points, 0.2 mL of release medium was withdrawn and replaced with an equal volume of fresh medium. The amounts of released DTX and PLB were quantified by HPLC. In vitro anti-tumor and radiosensitizing properties of (DTX + PLB)-NP Cellular uptake of the nanoformulations was evaluated by flow cytometry and confocal laser scanning microscopy (CLSM). LLC or A549 cells (2 × 105 cells per well) were seeded in 6-well plates or confocal dishes and allowed to adhere overnight. The cells were then incubated with PBS, rhodamine-loaded NT-(DTX + PLB)-NP, or rhodamine-loaded (DTX + PLB)-NP containing 0.05% (w/w) rhodamine. The final concentrations of DTX and PLB were both 1 μmol/L. After 6 h of incubation, the percentage of rhodamine-positive cells was determined by flow cytometry. For CLSM observation, the nuclei were stained with Hoechst 33342 by incubating the cells in PBS containing the fluorescent dye (1.0 mg/mL; 5.0 μL dye in 1.0 mL PBS, Solarbio, China) for 30 min before imaging. To verify whether the enhanced uptake of FA-modified nanoparticles was mediated by FR-dependent recognition, a free folic acid competition assay was performed. LLC and A549 cells were seeded in 6-well plates or confocal dishes and cultured overnight. Before nanoparticle treatment, the medium was replaced with folate-free DMEM, and cells were preincubated with free folic acid (1 mM) for 60 min. Cells were then treated with rhodamine-loaded FA-modified nanoparticles (NP.Rho) under the same conditions used for the cellular uptake assay. Cellular uptake was evaluated by flow cytometry and CLSM as described above. To evaluate cytotoxicity, LLC or A549 cells (5 × 103 cells per well) were seeded in 96-well plates and cultured for 20 to 24 h. The cells were then treated with PBS, FA-Blank-NP, free (DTX + PLB), NT-(DTX + PLB)-NP, or (DTX + PLB)-NP. The final concentration of the DTX + PLB combination was 1 μmol/L for LLC cells and 1.5 μmol/L for A549 cells. After 24 h of incubation, cell viability was measured using the MTT assay as described previously. For apoptosis analysis, LLC or A549 cells (2 × 105 cells per well) were seeded in 6-well plates and incubated for 20-24 h. The cells were then exposed to PBS, free (DTX + PLB), NT-(DTX + PLB)-NP, or (DTX + PLB)-NP and incubated for an additional 24 h. The proportion of apoptotic cells was quantified by flow cytometry using the previously described Annexin V-FITC/PI staining protocol. Radiosensitizing effects were further evaluated in LLC cells. Cells were seeded in 96-well plates at 5 × 103 cells per well and in 6-well plates at 2 × 105 cells per well, and cultured for 20 to 24 h. The experimental groups included PBS, free (DTX + PLB), (DTX + PLB)-NP, X-ray, X-ray + free (DTX + PLB), and X-ray + (DTX + PLB)-NP. The concentration of the DTX + PLB combination was 0.5 μmol/L in all drug-treated groups. After treatment with free (DTX + PLB) or (DTX + PLB)-NP for 24 h, cells were irradiated with 2 Gy using an X-ray generator (X-RAD 320, USA) at a dose rate of 1.02 Gy/min. Cells were then incubated for another 24 h. Cytotoxicity was assessed by the MTT assay, and apoptosis was analyzed by flow cytometry as described above. To further evaluate the dose-response relationship of (DTX + PLB)-NP combined with radiotherapy at lower concentrations, LLC cells were treated with different concentrations of (DTX + PLB)-NP for 24 h, with or without subsequent X-ray irradiation at 2 Gy as described above. The tested total drug concentrations of the DTX + PLB combination were 0, 0.125, 0.25, 0.5, and 1 μmol/L, consistent with the concentration definition used in the radiosensitization assay. After irradiation, cells were incubated for an additional 24 h, and cell viability was measured using the MTT assay. For the clonogenic assay, LLC cells were seeded in 6-well plates at a density of 500 cells per well and cultured for 20 to 24 h. The experimental groups were the same as those used for the radiosensitization assay, including PBS, free (DTX + PLB), (DTX + PLB)-NP, X-ray, X-ray + free (DTX + PLB), and X-ray + (DTX + PLB)-NP. The concentration of the DTX + PLB combination was 0.5 μmol/L in all drug-treated groups. After 24 h of drug treatment, the irradiation groups received 2 Gy X-ray irradiation at a dose rate of 1.02 Gy/min. After irradiation, cells were cultured for up to 14 days. Between days 10 and 14, colonies were fixed with methanol (1 mL per well) and stained with crystal violet solution (1 mL per well, 50 μg/mL). Colonies containing >50 cells were counted. Plating efficiency (PE) was defined as the ratio of the number of colonies formed to the number of cells initially seeded. The survival fraction (SF) was calculated as the ratio of PE in the treatment group to PE in the control group [30]. To measure intracellular ROS levels, LLC cells (2 × 105 cells per well) were seeded in 6-well plates and confocal dishes and cultured overnight. After the indicated treatments, ROS generation was evaluated using the ROS detection method described above. DNA damage was further examined by assessing the expression of the DNA damage marker γ-H2AX using CLSM. LLC cells (2 × 105 cells/well) were seeded in confocal dishes and cultured overnight. After treatment according to the experimental groups, the cells were washed with PBS and fixed with 4% paraformaldehyde, followed by permeabilization with Triton X-100. γ-H2AX primary antibody (Santa Cruz Biotechnology, sc-517348, 1:100) was added according to the manufacturer's instructions. After incubation, the cells were treated with a secondary antibody, anti-mouse IgG (H + L) (Jackson ImmunoResearch, 715-545-150, 1:300). Nuclei were counterstained with Hoechst 33342. Fluorescence images were acquired by CLSM, and γ-H2AX expression was quantified using ImageJ software. In vivo biosafety, pharmacokinetics, biodistribution and pharmacodynamics Healthy mice received tail vein injections of PBS or (DTX + PLB)-NP. The doses used were 4 mg/kg for DTX and 1 mg/kg for PLB, with a DTX to PLB molar ratio of 1:1. Body weight was recorded every 2 days for 28 days to assess systemic toxicity (n = 6). The pharmacokinetics of DTX and PLB in (DTX + PLB)-NP were evaluated in LLC tumor-bearing mice (n = 4). When the tumor volume reached approximately 150 mm3 (calculated using the formula (1/2) × a2b, where a is the minor diameter and b is the major diameter), the mice were intravenously administered either free drugs or (DTX + PLB)-NP (4 mg/kg DTX and 1 mg/kg PLB). Blood samples were collected at predetermined time points. The plasma concentrations of DTX and PLB were quantified by HPLC, and pharmacokinetic parameters were determined using DAS 2.0 software. The biodistribution of (DTX + PLB)-NP was assessed in the same LLC tumor model (n = 6). When the tumor volume reached approximately 250 mm3 (calculated using the same formula), mice were administered a tail vein injection of DiD-loaded nanoformulations (0.1 wt% DiD). After 6 h, the distribution of the nanoformulations was evaluated using the IVIS® Imaging System (644 nm/665 nm). The in vivo antitumor efficacy of (DTX + PLB)-NP was also investigated in LLC tumor-bearing mice (n = 6). Tumor volumes were measured every two days. When the tumor volume reached approximately 150 mm3, mice were randomized into four groups: PBS, free (DTX + PLB), NT-(DTX + PLB)-NP, and (DTX + PLB)-NP (n = 6). On days 0, 2, 4, 6, 8, 10, and 12, mice were intravenously injected with PBS or the corresponding formulations at doses of 4 mg/kg DTX and 1 mg/kg PLB. Mice were euthanized on day 14 by CO2 inhalation. Tumors were excised, weighed, and photographed. The tumor inhibition rate (TIR) was calculated using the formula: TIR = (1 - WT/WC) × 100%, where WT represents the average tumor weight in the experimental group and WC represents the average tumor weight in the control group [31]. In vivo anti-tumor study of (DTX + PLB)-NP combined with radiotherapy To evaluate the therapeutic efficacy of the nanoformulation in combination with radiotherapy for NSCLC, a syngeneic tumor model was established by subcutaneous injection of LLC cells into C57BL/6J mice, as described previously. Tumor volumes were measured every 2 days using a caliper, and body weights were recorded daily. Mice were euthanized by CO2 inhalation if the tumor diameter exceeded 2 cm or if body weight loss exceeded 20%. When the tumors reached an approximate volume of 150 mm3 (calculated as described above), the mice were randomized into six treatment groups: PBS, free (DTX + PLB), (DTX + PLB)-NP, X-ray, X-ray + free (DTX + PLB), and X-ray + (DTX + PLB)-NP (n = 6). On days 0, 3, and 6, the mice received intravenous tail vein injections of PBS, free (DTX + PLB), or (DTX + PLB)-NP via the tail vein. On days 1, 4, and 7, the mice were irradiated with 2 Gy at a dose rate of 1.02 Gy/min using an X-ray generator (X-RAD 320, USA), as shown in Fig. 8A [32]. To evaluate tumor weight and pathological characteristics, the mice were euthanized on day 14. Tumors were excised, weighed, photographed, and fixed in 4% paraformaldehyde before being embedded in paraffin. Major organs were collected for histopathological analysis using hematoxylin and eosin (H&E) staining. The TIR was calculated as previously described. Tissue sections of 12 μm thickness were prepared from paraffin-embedded samples using a rotary microtome (Leica RM 2245, Germany). The sections were stained with H&E and examined under a light microscope (BX51T, Olympus, Japan). For immunofluorescence analysis, the sections were incubated with a primary antibody against γ-H2AX (Santa Cruz Biotechnology, sc-517348, 1:100) and a secondary antibody, anti-mouse IgG (H + L) (Jackson ImmunoResearch, 715-545-150, 1:300), following the manufacturer's instructions. Apoptotic tumor cells were stained using a TUNEL staining kit (Meilun, China) and visualized using CLSM. Quantification of the staining was performed using ImageJ software. Additionally, whole blood and serum were collected for blood analysis and assessment of hepatic and renal function (Wuhan Service-Bio Technology, China). Statistical analysis All quantitative data are reported as the mean ± SD. Statistical comparisons between two groups were analyzed using an unpaired two-tailed Student's t-test, which was specifically employed for comparing protein expression levels from Western blot, drug half-lives, and blood toxicity assays. For data involving three or more groups, one-way analysis of variance (ANOVA) was used, followed by Tukey's or Bonferroni's multiple comparisons test as specified in the corresponding figure legends. Time-course data, including in vitro drug release kinetics and tumor volume, were assessed by two-way ANOVA followed by Tukey's post-hoc test. Mouse body weight monitoring and plasma drug concentration profiles were analyzed by two-way ANOVA with Sidak's multiple comparison correction. All analyses were conducted using GraphPad Prism 8.0 software, and a difference was considered statistically significant at p < 0.05. Results and discussion Screening based on redox modulation identifies PLB as a potent sensitizer of DTX chemotherapy Tumor cells rely on adaptive redox mechanisms to maintain survival, and disrupting this balance by inducing a surge in ROS offers a promising strategy to combat drug resistance. To this end, we developed a targeted screening library of natural ROS inducers, including PLB, celastrol (CLT), sanguinarin (SNG), dihydrotanshinone I (DIH), ziyuglycoside II (ZGS II), alantolactone (ALT), oridonin (ORI), and artesunate (ART) [[33], [34], [35], [36], [37], [38], [39], [40]], aiming to identify compounds that could synergize effectively with DTX. Cytotoxicity screening in LLC cells (Fig. 2A) revealed that PLB exhibited the most pronounced antitumor activity among the tested natural products. Dose-response analysis further confirmed that the half-maximal inhibitory concentrations (IC50) for PLB were 2.8 μmol/L in LLC cells and 3.2 μmol/L in A549 cells (Fig. 2B).Fig. 2PLB is a potent sensitizer of DTX and produces marked synergistic effects in NSCLC cells.(A) Cell viability (%) and IC50 values of several natural ROS-inducing agents in LLC cells (24 h, n = 3). (B) IC50 values of DTX in LLC and A549 cells (24 h, n = 3). (C) Molecular docking simulation illustrating a predicted interaction mode between PLB and DTX. (D) IC50 values of PLB in LLC and A549 cells (24 h, n = 3). (E, F) Synergistic effects of combined DTX and PLB treatment in LLC and A549 cells (24 h, n = 3). PLB is a potent sensitizer of DTX and produces marked synergistic effects in NSCLC cells. (A) Cell viability (%) and IC50 values of several natural ROS-inducing agents in LLC cells (24 h, n = 3). (B) IC50 values of DTX in LLC and A549 cells (24 h, n = 3). (C) Molecular docking simulation illustrating a predicted interaction mode between PLB and DTX. (D) IC50 values of PLB in LLC and A549 cells (24 h, n = 3). (E, F) Synergistic effects of combined DTX and PLB treatment in LLC and A549 cells (24 h, n = 3). To explore the possible molecular compatibility between PLB and DTX, we performed molecular docking analysis using AutoDock Vina. The docking results showed that PLB and DTX may form a spatially compatible interaction, with a predicted binding affinity of −2.919 kcal/mol (Fig. 2C). Structural visualization suggested possible hydrogen-bonding and π-π stacking interactions between the two molecules, including two predicted hydrogen bonds with distances shorter than 3.5 Å, namely 2.4 Å and 2.8 Å. These predicted non-covalent interactions suggest that PLB and DTX may possess a certain degree of molecular compatibility. After exploring the possible molecular compatibility between PLB and DTX, we next assessed the baseline sensitivity of NSCLC cells to DTX. The IC50 values for DTX were 20 μmol/L in LLC cells and 22 μmol/L in A549 cells (Fig. 2D), indicating that relatively high doses of DTX are required to achieve therapeutic efficacy. To quantify the pharmacological interaction between PLB and DTX, we calculated the combination index (CI) using the Chou-Talalay method. At an optimal molar ratio of 1:1, the two agents demonstrated strong synergistic effects, with a CI value of less than 1 (Fig. 2E and F). In LLC cells, the combination treatment reduced the IC50 of DTX from 20 μmol/L to 0.6 μmol/L, representing a 33.3-fold increase in sensitivity, while the effective concentration of PLB simultaneously decreased to 0.6 μmol/L (Fig. 2E and Fig. S1). A similar synergistic effect was observed in A549 cells, where sensitization was enhanced by approximately 18-fold (Fig. 2F and Fig. S2). These findings strongly support our hypothesis that PLB significantly reduces the effective dose of DTX while preserving its antitumor efficacy. The combination therapy thus achieves a therapeutic effect greater than the sum of its individual components (1 + 1 > 2), aligning with the goal of achieving high efficacy with low toxicity. Consequently, the 1:1 M ratio was selected as the optimal synergistic ratio for subsequent experiments. Redox modulation by PLB reshapes cell death pathways and enhances DTX chemosensitivity To investigate the molecular basis of the observed synergistic effect, we examined how PLB modulates cell death pathways in NSCLC cells. Flow cytometric analysis using Annexin V-FITC/PI dual staining (p < 0.001, Fig. 3A, Fig. S3) revealed the cytotoxic profile of PLB. This treatment induced apoptosis in LLC and A549 cells in a time-dependent manner. As the exposure time increased from 6 to 24 h, the percentage of apoptotic cells steadily rose, suggesting that PLB not only initiated but also sustained the apoptotic process. Western blot analysis (Fig. 3B, Fig. S4) further clarified the molecular mechanisms involved. PLB treatment significantly reduced the expression of the anti-apoptotic protein BCL-2 (p < 0.05) and increased the levels of the pro-apoptotic protein BAX (p < 0.05). This shift in the BCL-2/BAX ratio, functioning as a molecular rheostat, was associated with the cleavage and activation of the downstream effector caspase-3 (p < 0.05), indicating activation of the intrinsic apoptotic pathway [41,42].Fig. 3PLB induces apoptosis in NSCLC cells through ROS-mediated mitochondrial dysfunction.(A) Apoptosis (%) in LLC and A549 cells treated with PLB (3 μmol/L), assessed by Annexin V-FITC and PI double staining followed by flow cytometry. Quantitative analysis is shown in Fig. S3. (B) Western blot analysis of apoptosis-related proteins in LLC and A549 cells after 24 h treatment with PLB, including BCL-2, BAX, cleaved-caspase 3, and total caspase 3. Densitometric analysis is shown in Fig. S4. (C) ROS levels in LLC and A549 cells treated with PLB (n = 3). Data are presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (D) Rescue experiment with the ROS scavenger NAC (24 h). Quantitative data are shown in Fig. S5. (E) CLSM images of JC-1 stained cells used to evaluate changes in MMP. Red fluorescence (JC-1 aggregates) indicates a high membrane potential, while green fluorescence (JC-1 monomers) indicates a low membrane potential. Scale bar, 40 μm. Statistical analysis of the quantitative data in (C) was performed by one-way ANOVA followed by Tukey's multiple comparisons test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) PLB induces apoptosis in NSCLC cells through ROS-mediated mitochondrial dysfunction. (A) Apoptosis (%) in LLC and A549 cells treated with PLB (3 μmol/L), assessed by Annexin V-FITC and PI double staining followed by flow cytometry. Quantitative analysis is shown in Fig. S3. (B) Western blot analysis of apoptosis-related proteins in LLC and A549 cells after 24 h treatment with PLB, including BCL-2, BAX, cleaved-caspase 3, and total caspase 3. Densitometric analysis is shown in Fig. S4. (C) ROS levels in LLC and A549 cells treated with PLB (n = 3). Data are presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (D) Rescue experiment with the ROS scavenger NAC (24 h). Quantitative data are shown in Fig. S5. (E) CLSM images of JC-1 stained cells used to evaluate changes in MMP. Red fluorescence (JC-1 aggregates) indicates a high membrane potential, while green fluorescence (JC-1 monomers) indicates a low membrane potential. Scale bar, 40 μm. Statistical analysis of the quantitative data in (C) was performed by one-way ANOVA followed by Tukey's multiple comparisons test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Next, we examined the role of ROS in mediating this process. Flow cytometric analysis (Fig. 3C) revealed that PLB caused a significant, time-dependent accumulation of intracellular ROS, reaching its peak at 24 h (p < 0.001). Further ROS-scavenging experiments using NAC (Fig. 3D, Fig. S5) provided evidence of ROS involvement. Co-treatment with the ROS scavenger NAC significantly reduced PLB-induced apoptosis (p < 0.01), demonstrating that ROS production serves as an upstream signal initiating PLB-mediated cell death. To further determine whether ROS accumulation functionally contributes to the synergistic cytotoxicity of DTX and PLB, we performed NAC rescue experiments. NAC significantly attenuated DTX + PLB-induced cytotoxicity and partially restored cell viability in NSCLC cells (Fig. S6). These results indicate that ROS accumulation is not merely a concomitant event, but an important functional mediator of the synergistic antitumor effect of DTX and PLB. To visualize the effect of ROS on mitochondrial integrity, we assessed the MMP using the JC-1 probe (Fig. 3E). Confocal microscopy revealed that control cells exhibited intense red fluorescence from JC-1 aggregates, indicating a high MMP. In contrast, as PLB exposure increased from 6 to 24 h, the red fluorescence gradually diminished, while green fluorescence from JC-1 monomers, indicative of a reduced MMP, became more prominent. The significant decrease in the red-to-green fluorescence ratio suggested a sustained loss of MMP [43,44]. Notably, the temporal pattern of MMP loss closely paralleled the kinetics of ROS accumulation and apoptosis, further supporting that PLB disrupts mitochondrial function through oxidative stress and promotes mitochondria-associated apoptotic signaling [45]. These findings also help explain why PLB was selected as the oxidative priming agent in this chemoradiotherapy strategy. The advantage of PLB is not limited to increasing ROS levels. Many reported ROS-based radiosensitizers mainly act through exogenous catalytic ROS generation, high-Z element-mediated physical dose enhancement, or microenvironment-responsive oxidative stress amplification. In contrast, PLB is a redox-active small-molecule naphthoquinone that can perturb intracellular redox homeostasis. In this study, PLB induced time-dependent ROS accumulation, reduced mitochondrial membrane potential, shifted BCL-2/BAX signaling toward apoptosis, and activated caspase-3. Moreover, NAC partially attenuated PLB- or DTX/PLB-induced cytotoxicity, supporting the functional involvement of ROS. These results suggest that PLB may act as an oxidative primer by lowering the oxidative stress tolerance and apoptotic threshold of NSCLC cells, thereby creating a vulnerable state for DTX-mediated cytotoxicity and X-ray-induced oxidative DNA damage. Thus, in this study, the value of PLB lies in its experimentally supported ROS amplification, apoptotic priming, and synergy with DTX. These features provide a pharmacological basis for the subsequent development of a ratio-controlled DTX/PLB liposomal co-delivery system. Engineering of the nano co-delivery system and physicochemical characterization The combination of DTX and PLB demonstrated significant synergistic effects at the cellular level. However, their distinct physicochemical properties present a major challenge for clinical application. To address the pharmacokinetic mismatch that hinders synergy, we engineered a FA-targeted, PEG-modified liposomal nanoformulation, denoted (DTX + PLB)-NP, using a thin-film hydration method. This design aims to align the pharmacokinetic profiles of both agents, enabling their spatiotemporal synchronization during co-delivery (Fig. 4A).Fig. 4Characterization of FA-targeted (DTX + PLB)-NP nanocarrier and its in vitro release properties.(A) Schematic of the fabrication process for (DTX + PLB)-NP using the thin-film hydration method. (B) TEM imaging of (DTX + PLB)-NP. Scale bar, 200 nm. (C, D) DLS analysis of the particle size distribution of (DTX + PLB)-NP and the non-targeted control NT-(DTX + PLB)-NP (C), and summary of the hydrodynamic diameter, PDI, zeta potential, EE and LC (D) (n = 3). (E) In vitro pH-responsive release profiles of DTX and PLB from (DTX + PLB)-NP at different pH conditions (pH 5.5, 6.8 and 7.4) 72 h (n = 3). (F) Changes in the particle size of (DTX + PLB)-NP after storage at 4 °C for 0, 7, 14, 21 and 28 days (n = 3). Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparisons test for (E), or one-way ANOVA followed by Tukey's multiple comparisons test for (F). ∗∗p < 0.01, ∗∗∗p < 0.001; ns, not significant. Characterization of FA-targeted (DTX + PLB)-NP nanocarrier and its in vitro release properties. (A) Schematic of the fabrication process for (DTX + PLB)-NP using the thin-film hydration method. (B) TEM imaging of (DTX + PLB)-NP. Scale bar, 200 nm. (C, D) DLS analysis of the particle size distribution of (DTX + PLB)-NP and the non-targeted control NT-(DTX + PLB)-NP (C), and summary of the hydrodynamic diameter, PDI, zeta potential, EE and LC (D) (n = 3). (E) In vitro pH-responsive release profiles of DTX and PLB from (DTX + PLB)-NP at different pH conditions (pH 5.5, 6.8 and 7.4) 72 h (n = 3). (F) Changes in the particle size of (DTX + PLB)-NP after storage at 4 °C for 0, 7, 14, 21 and 28 days (n = 3). Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparisons test for (E), or one-way ANOVA followed by Tukey's multiple comparisons test for (F). ∗∗p < 0.01, ∗∗∗p < 0.001; ns, not significant. TEM imaging (Fig. 4B) revealed that (DTX + PLB)-NP displayed a well-defined, compact, and uniform spherical morphology. DLS analysis (Fig. 4C and D) showed a mean hydrodynamic diameter of approximately 145 nm and a low PDI of 0.10, indicating a highly monodisperse population. Notably, FA modification resulted in a particle size increase of approximately 37 nm compared to the non-targeted liposomes, NT-(DTX + PLB)-NP (diameter ∼108 nm, PDI ∼0.18) (Fig. 4D), supporting the successful integration of DSPE-PEG2000-FA polymer chains onto the lipid bilayer surface and the formation of a hydrated steric barrier. Zeta potential measurements revealed a negative surface charge of −32 ± 1 mV, contributing to colloidal stability through electrostatic repulsion [46,47]. Precise control of the drug ratio is crucial for translating in vitro synergy into in vivo efficacy. HPLC analysis confirmed that (DTX + PLB)-NP had high encapsulation efficiencies of 91% for DTX and 88% for PLB, with drug LC of approximately 6 wt% for DTX and 1.4 wt% for PLB. These findings demonstrate that the nanoformulation successfully co-encapsulated DTX and PLB at a molar ratio of approximately 1:1 (Fig. 4D), establishing a foundation for ratio-dependent synergistic killing in subsequent experiments. In vitro release studies showed pH-dependent and sustained release of both DTX and PLB from (DTX + PLB)-NP (Fig. 4E). Acidic conditions accelerated drug release compared with physiological pH 7.4, with the highest cumulative release observed at pH 5.5. At 72 h, drug release at pH 5.5 was approximately 1.8-1.9-fold higher than that at pH 7.4 and 1.1-1.2-fold higher than that at pH 6.8. The extended 72 h profile further showed gradual release beyond 24 h without an early plateau, supporting a sustained release pattern. In contrast, release at pH 7.4 remained slower throughout the study, suggesting reduced premature leakage under physiological conditions. This pH-dependent release behavior may facilitate drug retention during systemic circulation while promoting enhanced release in acidic tumor-related microenvironments or intracellular compartments. In formulations without specific pH-sensitive lipids, the accelerated release under acidic conditions may be attributed to perturbation of the lipid bilayer surface charge or local hydration layer at lower pH. These changes may reduce lipid packing density or slightly increase membrane fluidity, thereby weakening the membrane barrier and facilitating drug diffusion, which is consistent with previous reports showing that pH changes can destabilize liposomal membranes and accelerate cargo release [48]. Moreover, DTX and PLB showed broadly coordinated release trends under the same pH conditions, which may help preserve the optimized synergistic ratio after co-delivery. Furthermore, the particle size of (DTX + PLB)-NP remained below 200 nm after 14 days of storage at 4 °C (Fig. 4F). The 100-200 nm range is considered the “golden window” for passive accumulation through the EPR effect [49]. Although there was a slight increase in size after 21 days of storage, the formulation demonstrated adequate physical stability during the first two weeks, making it suitable for immediate use and short-term storage for subsequent biological evaluations. Beyond the measured physicochemical characteristics, the formulation design of (DTX + PLB)-NP was guided by both the ratio-dependent synergy between DTX and PLB and established principles of liposomal nanomedicine. The DTX:PLB molar ratio of 1:1 was selected not merely because the CI value was below 1, but because it produced a robust and relatively balanced synergistic effect in both NSCLC cell models. In LLC cells, this ratio generated the lowest CI value and reduced the effective DTX concentration from 20 μmol/L to 0.6 μmol/L, corresponding to a 33.3-fold sensitization effect. In A549 cells, the same ratio also maintained clear synergism and improved DTX sensitivity by approximately 18-fold. Therefore, this ratio was selected for liposomal co-encapsulation to preserve the optimized synergistic proportion during tumor delivery, cellular uptake, and intracellular release. Although (DTX + PLB)-NP was designed as an actively targeted formulation, passive tumor accumulation remains an important prerequisite for efficient in vivo nanodelivery. The final hydrodynamic diameter of approximately 145 nm falls within the commonly discussed 100-200 nm range considered favorable for prolonged circulation and EPR-associated tumor accumulation, although EPR-mediated delivery can vary substantially among tumor types and patients because of differences in vascular permeability, interstitial pressure, and lymphatic drainage [50]. In this context, FA modification provides a second-level targeting mechanism by enhancing FR-mediated binding and internalization after nanoparticles reach the tumor region, rather than replacing passive accumulation. FA modification increased the hydrodynamic diameter by approximately 37 nm, which may partly reflect the contribution of the hydrated PEG/FA ligand layer to the hydrodynamic diameter measured by DLS. Although this moderate size increase may affect tissue penetration and circulation behavior, the final formulation remained within a nanoscale range suitable for systemic delivery and EPR-associated tumor localization. In addition, the low PDI of 0.10 indicates good size uniformity, while the negative zeta potential of −32 ± 1 mV may contribute to colloidal stability and reduce nonspecific aggregation during circulation. PEGylation was another key design consideration. The PEG layer can improve colloidal stability and prolong systemic circulation by reducing serum protein adsorption and reticuloendothelial clearance, thereby increasing the opportunity for EPR-associated tumor accumulation [51]. However, PEG coverage may also introduce steric shielding, potentially weakening nanoparticle-cell membrane interactions and limiting cellular internalization. Thus, formulation design requires a balance between circulation stability and tumor cell uptake. FA functionalization was incorporated to provide an active targeting component intended to promote FR-mediated binding and endocytosis after tumor localization. For tumors with different FR expression levels, future formulation optimization should be guided by FR expression profiling rather than a fixed ligand configuration. In FR-high tumors, maintaining an appropriate FA ligand density may enhance multivalent binding and FR-mediated endocytosis. In contrast, for tumors with low or heterogeneous FR expression, simply increasing FA density may not proportionally improve targeting efficacy, because receptor availability, ligand exposure, PEG shielding, and nanoparticle size jointly determine cellular binding and internalization [52]. In such settings, optimization may involve tuning FA ligand density, adjusting PEG coverage or linker exposure, or incorporating additional targeting ligands to improve delivery across FR-heterogeneous tumor populations [53]. Overall, (DTX + PLB)-NP exhibited key pharmaceutical features required for a ratio-controlled co-delivery platform. Its nanoscale size of approximately 145 nm may support prolonged circulation and EPR-associated tumor accumulation, while the PEG layer contributes to colloidal and circulatory stability. The pH-dependent, sustained, and broadly coordinated release profiles of DTX and PLB provide a pharmaceutical basis for maintaining the optimized drug ratio and achieving combined intratumoral exposure. Importantly, this formulation was not designed simply as two separately nanoencapsulated drugs, but as a ratio-controlled co-delivery system. Its therapeutic rationale depends on the coordinated action of PLB-mediated oxidative priming and DTX-mediated cytotoxicity within the same delivery platform. Therefore, maintaining the optimized DTX/PLB ratio and synchronized delivery is critical for preserving the intended chemoradiotherapeutic sensitization effect. The nanoparticle formulation exhibits in vitro anti-NSCLC activity To assess the targeted delivery capability of the nanoformulation, we first evaluated cellular uptake using rhodamine-labeled nanoparticles. CLSM images (Fig. 5A) revealed that FA-modified NP.Rho exhibited significantly stronger red fluorescence signals in the cytoplasm of both LLC and A549 cells relative to the non-targeted NT-NP.Rho group. The fluorescence was diffusely distributed around the blue-stained nuclei. Flow cytometric analysis (Fig. 5B) further corroborated that the mean fluorescence intensity (MFI) of the targeted nanoparticles was significantly higher than that of the non-targeted nanoparticles (p < 0.001). To validate FR-mediated uptake, we performed free folic acid competition experiments. Free folic acid pretreatment reduced NP.Rho uptake in both LLC and A549 cells, as shown by decreased rhodamine fluorescence in CLSM images and flow cytometry analysis (Fig. S7 and S8). These results support that the enhanced uptake of FA-modified nanoparticles is at least partly FR-dependent.Fig. 5FR-mediated active targeting enhances cellular uptake and in vitro antitumor activity of the nanoformulation in NSCLC cells.(A) Qualitative assessment of intracellular uptake of non-targeted NPs (NT-NP.Rho) and targeted NPs (NP.Rho) in LLC and A549 cells by CLSM. Blue fluorescence indicates Hoechst 33342-stained nuclei, and red fluorescence indicates internalized NPs. (B) Quantitative analysis of cellular uptake of different nanoformulations by LLC and A549 cells after 6 h of incubation, measured by flow cytometry. Representative histograms are shown on the left, and mean fluorescence intensity values are summarized on the right (n = 3). (C) Cell viability of LLC and A549 cells treated with blank carrier (FA-Blank-NP), free drug (Free), non-targeted nanoparticles (NT-NP), or targeted nanoparticles (NP), as determined by the MTT assay (24 h, n = 3). FA-Blank-NP refers to drug-free FA-modified PEGylated liposomes containing the FA-PEG-lipid component but without DTX or PLB. The final concentration of the DTX + PLB combination was 1 μmol/L for LLC cells and 1.5 μmol/L for A549 cells. (D) Apoptosis induced by the different formulations of treatment, evaluated by Annexin V-FITC and PI double staining followed by flow cytometry (24 h, n = 3). Representative dot plots are shown on the left, and total apoptosis rates (early plus late apoptosis) are quantified on the right. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple comparisons test for (B-D). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; n.s. = not significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) FR-mediated active targeting enhances cellular uptake and in vitro antitumor activity of the nanoformulation in NSCLC cells. (A) Qualitative assessment of intracellular uptake of non-targeted NPs (NT-NP.Rho) and targeted NPs (NP.Rho) in LLC and A549 cells by CLSM. Blue fluorescence indicates Hoechst 33342-stained nuclei, and red fluorescence indicates internalized NPs. (B) Quantitative analysis of cellular uptake of different nanoformulations by LLC and A549 cells after 6 h of incubation, measured by flow cytometry. Representative histograms are shown on the left, and mean fluorescence intensity values are summarized on the right (n = 3). (C) Cell viability of LLC and A549 cells treated with blank carrier (FA-Blank-NP), free drug (Free), non-targeted nanoparticles (NT-NP), or targeted nanoparticles (NP), as determined by the MTT assay (24 h, n = 3). FA-Blank-NP refers to drug-free FA-modified PEGylated liposomes containing the FA-PEG-lipid component but without DTX or PLB. The final concentration of the DTX + PLB combination was 1 μmol/L for LLC cells and 1.5 μmol/L for A549 cells. (D) Apoptosis induced by the different formulations of treatment, evaluated by Annexin V-FITC and PI double staining followed by flow cytometry (24 h, n = 3). Representative dot plots are shown on the left, and total apoptosis rates (early plus late apoptosis) are quantified on the right. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple comparisons test for (B-D). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; n.s. = not significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Notably, although FR is generally highly expressed in NSCLC, A549 cells are traditionally considered low FR-expressing cell lines. However, in this study, a significant FA-mediated targeting enhancement effect was observed in A549 cells. This phenomenon can be attributed to the multivalent binding avidity of the nanoparticle platform. Unlike free ligands, the high-density FA ligands on the nanoparticle surface can form multipoint cooperative binding with the relatively low-density receptors on the cell surface [54]. This clustering effect significantly enhances binding avidity, allowing efficient receptor-mediated endocytosis even in cells with relatively low receptor density. This is consistent with recent findings in targeted delivery for NSCLC [55,56]. Benefiting from this efficient targeted internalization and coordinated intracellular release, (DTX + PLB)-NP exhibited the most potent antitumor activity. MTT assays (Fig. 5C) indicated that treatment with FA-Blank-NP (the drug-free FA-modified PEGylated liposomal carrier) maintained cell viability near 100%, indicating excellent biocompatibility of the liposomal carrier. In contrast, drug-loaded formulations significantly inhibited cell proliferation, with the targeted NP group exhibiting the lowest viability (less than 25% in LLC cells and less than 30% in A549 cells). The cytotoxic effect of the targeted nanoparticles was markedly stronger than that of free drugs and non-targeted nanoparticles. Apoptosis analysis (Fig. 5D) further demonstrated that (DTX + PLB)-NP induced extensive programmed cell death. The total apoptosis rate, including both early and late apoptosis, reached approximately 60% in NSCLC cells, significantly higher than that in any other treatment group. These findings suggest that the nanoformulation may function in a “Trojan horse"-like manner by enhancing intracellular delivery of the co-loaded drugs, thereby promoting efficient activation of apoptotic pathways. Collectively, these results highlight the substantial potential of nanotechnology-enabled co-delivery to overcome drug resistance and enhance therapeutic efficacy. NP enhanced the sensitivity of NSCLC cells to chemoradiotherapy in vitro Given the redox-modulatory activity of PLB and the microtubule-stabilizing effect of DTX, we hypothesized that the co-loaded nanoparticles could serve as dual sensitizers, overcoming the intrinsic radioresistance of NSCLC cells. MTT assays (Fig. 6A) demonstrated that X-ray irradiation at 2 Gy alone moderately inhibited cell growth, whereas the combination treatments elicited a significantly stronger effect. Notably, the X-ray + (DTX + PLB)-NP group exhibited the lowest cell viability, which dropped to below 20% and was significantly lower than that of the X-ray + free drug group (p < 0.001). Consistent with these findings, flow cytometric analysis of apoptosis (Fig. 6B, S9) revealed that X-ray + (DTX + PLB)-NP induced the highest apoptotic rate, reaching 68%, which was markedly higher than in the X-ray + free drug group (47%) and the radiation-only group (22%). These data suggest a synergistic lethality, wherein the nano-delivery system enhances the intracellular accumulation of both drugs and maximizes the interaction between chemotherapy and radiotherapy. The different concentrations used in Fig. 5, Fig. 6 reflect different experimental purposes: Fig. 5 evaluated formulation cytotoxicity, whereas Fig. 6 used a lower concentration to preserve a measurable window for radiosensitization. We further examined a low-concentration gradient of (DTX + PLB)-NP combined with X-ray. X-ray significantly enhanced the cytotoxicity of (DTX + PLB)-NP across the tested concentration range, confirming a concentration-dependent radiosensitizing effect (Fig. S10).Fig. 6(DTX + PLB)-NP enhances the sensitivity of LLC cells to CCRT in vitro by inducing a ROS burst and aggravating DNA damage.(A) Inhibition of LLC cell viability by different treatment strategies, as determined by the MTT assay (n = 3). Treatment groups included PBS (Control), free DTX + PLB (Free), X-ray irradiation alone (X-ray), (DTX + PLB)-NP alone (NP), X-ray plus free DTX + PLB (X-ray + Free), and X-ray plus (DTX + PLB)-NP (X-ray + NP). The concentration of the DTX + PLB combination was 0.5 μmol/L in all drug-treated groups. (B) Apoptosis of LLC cells after the indicated treatments, analyzed by flow cytometry (n = 3). (C) Representative images of clonogenic assays. (D, E) Intracellular ROS levels after treatment with the different regimens, evaluated qualitatively by CLSM (D) and quantitatively by flow cytometry (E) (6h, n = 3). (F) DNA double strand breaks assessed by γ-H2AX immunofluorescence staining and visualized by CLSM. Blue fluorescence (Hoechst 33342) labels cell nuclei, and green fluorescence marks γ-H2AX foci. Scale bar, 40 μm. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple comparisons test for (A) and (E). ∗∗p < 0.01, ∗∗∗p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) (DTX + PLB)-NP enhances the sensitivity of LLC cells to CCRT in vitro by inducing a ROS burst and aggravating DNA damage. (A) Inhibition of LLC cell viability by different treatment strategies, as determined by the MTT assay (n = 3). Treatment groups included PBS (Control), free DTX + PLB (Free), X-ray irradiation alone (X-ray), (DTX + PLB)-NP alone (NP), X-ray plus free DTX + PLB (X-ray + Free), and X-ray plus (DTX + PLB)-NP (X-ray + NP). The concentration of the DTX + PLB combination was 0.5 μmol/L in all drug-treated groups. (B) Apoptosis of LLC cells after the indicated treatments, analyzed by flow cytometry (n = 3). (C) Representative images of clonogenic assays. (D, E) Intracellular ROS levels after treatment with the different regimens, evaluated qualitatively by CLSM (D) and quantitatively by flow cytometry (E) (6h, n = 3). (F) DNA double strand breaks assessed by γ-H2AX immunofluorescence staining and visualized by CLSM. Blue fluorescence (Hoechst 33342) labels cell nuclei, and green fluorescence marks γ-H2AX foci. Scale bar, 40 μm. Data are presented as mean ± SD. Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple comparisons test for (A) and (E). ∗∗p < 0.01, ∗∗∗p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Clonogenic assays further confirmed that the nanoformulation significantly compromised reproductive cell death. As shown in Fig. 6C and Fig. S11, the surviving fraction in the radiation-only group remained high at 0.61. In contrast, the surviving fraction in the X-ray + (DTX + PLB)-NP group dropped sharply to 0.16 (p < 0.001), which was significantly lower than that in the X-ray + free (DTX + PLB) group (0.42). These results indicate that the nanoformulation-based chemoradiotherapy not only triggers short-term apoptosis but also effectively suppresses the long-term clonogenic potential of tumor cells. Mechanistic studies suggested that this pronounced radiosensitizing effect was associated with a nanoformulation-induced ROS burst and enhanced DNA damage accumulation. As shown in Fig. 6D and E, combination treatment led to a marked increase in intracellular ROS. In the X-ray + (DTX + PLB)-NP group, ROS levels reached approximately 2.5 times those in the X-ray-only group and about 3.3 times those in the nanoformulation-only group. This intense oxidative stress may result from the combined effects of PLB-mediated redox perturbation, DTX-induced cytotoxic stress, and X-ray-induced ROS generation. This effect may also be supported by the reported redox-cycling property of PLB and its potential interference with antioxidant buffering systems. However, in the present study, the functional involvement of ROS was supported mainly by ROS accumulation and NAC rescue experiments. The sustained ROS increase may impose oxidative pressure beyond the cellular repair capacity, thereby contributing to γ-H2AX-associated DNA damage accumulation [23,24]. This model is supported by γ-H2AX immunofluorescence analysis (Fig. 6F), where the nuclei of cells in the combined treatment group exhibited intense diffuse fluorescence signals, indicating extensive γ-H2AX-associated DNA damage. Taken together, these findings indicate that (DTX + PLB)-NP reprograms the response of NSCLC cells to irradiation through a ROS burst coupled with catastrophic DNA damage. By establishing a ROS-to-DNA damage cascade, the nanoformulation effectively overcomes radioresistance and provides a robust cellular basis for highly efficient CCRT. Nanoformulation enables efficient and low-toxicity therapy in vivo through pharmacokinetic synchronization and active targeted accumulation To evaluate the translational potential of the oxidative priming strategy in vivo, we employed an optimized low-dose combination regimen (DTX 4 mg/kg, PLB 1 mg/kg, molar ratio 1:1) and systematically evaluated the biosafety, pharmacokinetics, and antitumor efficacy of (DTX + PLB)-NP. First, systemic safety assessments revealed that repeated intravenous administration of the nanoformulation did not cause significant body weight loss (Fig. S12). This indicates that the formulation has good overall tolerability and provides preliminary evidence of its in vivo biosafety. To address the clinical limitation of free drugs, which possess short half-lives and significantly different metabolic behaviors, we next evaluated their pharmacokinetic profiles (Fig. 7A and B). Free DTX and PLB were rapidly cleared from the circulation, with half-lives of approximately 1.08 h and 0.5 h, respectively. In contrast, the targeted co-loaded nanoparticles leveraged the stealth effect of the PEG shell, significantly prolonging the circulation half-lives of DTX and PLB to 2.57 h and 2.64 h, respectively. Importantly, nanoencapsulation not only extended drug exposure but also harmonized and synchronized the pharmacokinetics of both agents. As a result, DTX and PLB circulated together in a coordinated manner at an approximately 1:1 synergistic ratio, thereby facilitating effective tumor accumulation.Fig. 7In vivo biosafety, pharmacokinetics, biodistribution, and antitumor efficacy of the nanoformulation in tumor-bearing mice.(A, B) Pharmacokinetic analysis in LLC tumor-bearing mice after intravenous administration of free drugs or nanoformulation. The administered dose was 4 mg/kg DTX and 1 mg/kg PLB. (C) Representative in vivo fluorescence images showing the biodistribution of DiD-labeled non-targeted nanocarriers (NT-NP.DiD) and targeted nanocarriers (NP.DiD) at 6 h after tail vein injection in LLC tumor-bearing mice. (D, E) Ex vivo biodistribution analysis at 6 h after administration (n = 6). (F) In vivo antitumor efficacy study in LLC tumor-bearing mice. The treatment schedule and representative photographs of excised tumors collected at the end of treatment on day 14 are shown (n = 6). Treatment groups included PBS (Control), free DTX + PLB combination (Free), non-targeted NPs (NT-NP), and targeted co-loaded NPs (NP). (G) Mean tumor weights of mice in each treatment group at the experimental endpoint (n = 6). Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Sidak's multiple comparisons test for (A) and (E), two-tailed unpaired t-test for (B), and one-way ANOVA followed by Tukey's multiple comparisons test for (G). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.Fig. 8(DTX + PLB)-NP combined with radiotherapy markedly enhances in vivo CCRT sensitivity in NSCLC.(A) Treatment schedule for CCRT in LLC tumor-bearing mice. Mice received intravenous injections of drugs on days 0, 3, and 6 (4 mg/kg DTX and 1 mg/kg PLB) and were exposed to X-ray irradiation on days 1, 4, and 7 (2.0 Gy). (B) Representative photographs of excised tumors from each treatment group at the experimental endpoint, along with tumor volume growth curves recorded during the treatment period (n = 6). (C) Tumor weight of each group at the end of treatment (day 14), presented as a statistical comparison (n = 6). (D-F) Histopathological and mechanistic analyses of tumor tissues collected on day 14. (D) H&E staining showing the largest areas of tissue necrosis and the most extensive structural destruction in the combined treatment group. (E) TUNEL fluorescence images, where red signals indicate apoptotic cells and blue signals indicate nuclei. Quantitative analysis is shown in Fig. S13. (F) γ-H2AX immunofluorescence staining, where green signals indicate γ-H2AX-associated DNA damage, together with quantitative analysis of γ-H2AX fluorescence intensity. Data are presented as mean ± SD. Tumor growth curves in (B) were analyzed using two-way ANOVA followed by Tukey's multiple comparisons test. Endpoint tumor weights in (C) and γ-H2AX fluorescence quantification in (F) were analyzed using one-way ANOVA followed by Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. = not significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) In vivo biosafety, pharmacokinetics, biodistribution, and antitumor efficacy of the nanoformulation in tumor-bearing mice. (A, B) Pharmacokinetic analysis in LLC tumor-bearing mice after intravenous administration of free drugs or nanoformulation. The administered dose was 4 mg/kg DTX and 1 mg/kg PLB. (C) Representative in vivo fluorescence images showing the biodistribution of DiD-labeled non-targeted nanocarriers (NT-NP.DiD) and targeted nanocarriers (NP.DiD) at 6 h after tail vein injection in LLC tumor-bearing mice. (D, E) Ex vivo biodistribution analysis at 6 h after administration (n = 6). (F) In vivo antitumor efficacy study in LLC tumor-bearing mice. The treatment schedule and representative photographs of excised tumors collected at the end of treatment on day 14 are shown (n = 6). Treatment groups included PBS (Control), free DTX + PLB combination (Free), non-targeted NPs (NT-NP), and targeted co-loaded NPs (NP). (G) Mean tumor weights of mice in each treatment group at the experimental endpoint (n = 6). Data are presented as mean ± SD. Statistical analysis was performed using two-way ANOVA followed by Sidak's multiple comparisons test for (A) and (E), two-tailed unpaired t-test for (B), and one-way ANOVA followed by Tukey's multiple comparisons test for (G). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. (DTX + PLB)-NP combined with radiotherapy markedly enhances in vivo CCRT sensitivity in NSCLC. (A) Treatment schedule for CCRT in LLC tumor-bearing mice. Mice received intravenous injections of drugs on days 0, 3, and 6 (4 mg/kg DTX and 1 mg/kg PLB) and were exposed to X-ray irradiation on days 1, 4, and 7 (2.0 Gy). (B) Representative photographs of excised tumors from each treatment group at the experimental endpoint, along with tumor volume growth curves recorded during the treatment period (n = 6). (C) Tumor weight of each group at the end of treatment (day 14), presented as a statistical comparison (n = 6). (D-F) Histopathological and mechanistic analyses of tumor tissues collected on day 14. (D) H&E staining showing the largest areas of tissue necrosis and the most extensive structural destruction in the combined treatment group. (E) TUNEL fluorescence images, where red signals indicate apoptotic cells and blue signals indicate nuclei. Quantitative analysis is shown in Fig. S13. (F) γ-H2AX immunofluorescence staining, where green signals indicate γ-H2AX-associated DNA damage, together with quantitative analysis of γ-H2AX fluorescence intensity. Data are presented as mean ± SD. Tumor growth curves in (B) were analyzed using two-way ANOVA followed by Tukey's multiple comparisons test. Endpoint tumor weights in (C) and γ-H2AX fluorescence quantification in (F) were analyzed using one-way ANOVA followed by Tukey's multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n.s. = not significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Subsequent biodistribution imaging (Fig. 7C–E) validated the advantages of the FA ligand-mediated active targeting strategy. Six hours after a single administration, the fluorescence intensity of (DTX + PLB)-NP in tumor tissues was 3.3 times higher than that of the non-targeted NT-(DTX + PLB)-NP (p < 0.01), indicating that FA modification significantly enhanced tumor-localized accumulation of the nanocarrier. Notably, quantitative results shown in Fig. 7E revealed that targeting modification did not increase, but rather decreased, the non-specific retention of the drug in organs such as the liver and spleen, part of the reticuloendothelial system (p < 0.05). This finding suggests a potential to reduce off-target retention. Supported by pharmacokinetic synchronization and tumor-selective enrichment, (DTX + PLB)-NP exhibited potent antitumor activity in the LLC syngeneic tumor model (Fig. 7F and G). Compared to the control group, free DTX + PLB led to a moderate reduction in tumor growth (p < 0.01). However, the targeted nanoformulation exhibited significantly enhanced tumor suppression. The mean tumor weight in the (DTX + PLB)-NP group was only about one-third of that in the non-targeted NT-(DTX + PLB)-NP group (p < 0.01) and significantly lower than in the free drug group (p < 0.001). A particularly compelling observation is that the in vivo antitumor advantage of the targeted nanoparticles far exceeded the magnitude of their in vitro cytotoxicity difference. This discrepancy may be attributed to the dual-targeting mechanism of the FA ligand in the solid tumor microenvironment. Extrapolating from published studies in other tumor models [57], we hypothesize but cannot yet confirm in our NSCLC system that FA modification may provide an additional stromal-targeting effect beyond direct tumor cell uptake. Previous studies have identified FRβ as an enriched marker of M2-like tumor-associated macrophages (TAMs), and FA-modified nanoformulations have been reported to penetrate the stromal compartment and target FRβ-high TAMs. Therefore, the superior in vivo therapeutic efficacy of (DTX + PLB)-NP compared with free drugs and non-targeted nanoparticles may be partly associated with enhanced tumor cell uptake and may also involve potential interactions with the tumor microenvironment. However, we did not directly quantify FRβ expression on TAMs in the LLC tumor microenvironment or assess TAM depletion in this study. Thus, the possible involvement of FRβ-positive TAM targeting remains a hypothesis and requires dedicated experimental validation. Taken together, (DTX + PLB)-NP leverages the unique features of a nanomedicine delivery system, including prolonged circulation, synchronized co-delivery, and tumor-targeted accumulation. By overcoming the pharmacokinetic deficiencies of free drugs, it achieves highly effective combination therapy against NSCLC at low doses, with favorable preliminary short-term biosafety. NP enhanced the sensitivity of NSCLC cells to chemoradiotherapy in vivo Following the confirmation of the favorable pharmacokinetic and active targeting properties of the nanoformulation, we further assessed its therapeutic potential as a CCRT sensitizer in a syngeneic subcutaneous tumor model (Fig. 8A). Owing to the poor systemic bioavailability of free drugs, the low-dose combination of free DTX and PLB exhibited only modest antitumor activity, with a tumor inhibition rate (TIR) of 12% (Fig. 8B and C). In contrast, (DTX + PLB)-NP monotherapy increased the TIR to 63% (p < 0.01), which correlated with significantly enhanced intratumoral drug accumulation mediated by the nanoformulation. Upon the introduction of X-ray irradiation, the radiosensitizing capacity of the nanoformulation became strikingly apparent. The radiation-only group achieved a TIR of 52%, while the group receiving X-ray + free (DTX + PLB) reached a TIR of 82%. However, the X-ray + (DTX + PLB)-NP group resulted in nearly complete tumor regression, with a TIR of 99% (p < 0.001 vs. X-ray + free (DTX + PLB)). Tumor growth curves in this group were almost completely flat, with many tumors regressing to undetectable sizes. Histopathological analyses corroborated these findings. H&E staining demonstrated the largest necrotic areas and the most extensive disruption of tumor architecture in the X-ray + (DTX + PLB)-NP group (Fig. 8D). TUNEL staining revealed the highest apoptotic index across all groups, with red fluorescent signals distributed throughout the entire tumor sections (Fig. 8E, Fig. S13). Immunofluorescence staining for γ-H2AX (Fig. 8F) demonstrated the most intense and dense green nuclear foci in this group, indicating extensive DNA double-strand breaks. Collectively, these findings suggest that the nanoparticle formulation enhanced chemoradiotherapy-associated apoptosis and γ-H2AX-associated DNA damage in tumor tissues, consistent with the proposed oxidative priming mechanism. Compared with free (DTX + PLB), the enhanced radiosensitizing effect of (DTX + PLB)-NP may be primarily attributed to pharmacokinetic synchronization, active tumor accumulation, and sustained intratumoral drug exposure. Free DTX and PLB were rapidly cleared in vivo and exhibited mismatched half-lives of 1.08 h and 0.5 h, respectively, making it difficult to maintain the optimal 1:1 synergistic ratio within tumors during the irradiation window. Nanoencapsulation prolonged the circulation half-lives of DTX and PLB to 2.57 h and 2.64 h, respectively, thereby coordinating their systemic exposure and tumor delivery. Together with FA-mediated tumor accumulation and pH-dependent sustained release, this synchronized exposure may help sustain PLB-mediated oxidative priming and maintain a more persistent oxidative stress state after irradiation. This sustained oxidative burden could overwhelm cellular redox-buffering capacity and amplify γ-H2AX-associated DNA damage accumulation, which is consistent with the stronger ROS signals, higher γ-H2AX levels, and superior tumor inhibition observed in the X-ray + (DTX + PLB)-NP group. Importantly, this high-intensity antitumor efficacy was not accompanied by a significant safety penalty. Throughout the treatment course, body weight remained stable across the combination treatment groups (Fig. 9A). Hematological parameters and serum biochemical indices, including ALT, AST, BUN, and creatinine, remained within normal physiological ranges (Fig. 9B and C). Histological examination of major organs, including the heart, liver, spleen, lungs, and kidneys, showed no signs of pathological change, such as congestion, edema, or necrosis. These findings suggest that (DTX + PLB)-NP effectively mitigated the systemic toxicities commonly associated with conventional CCRT, such as myelosuppression and hepatorenal injury, thereby affording a wide therapeutic window.Fig. 9In vivo biosafety evaluation of (DTX + PLB)-NP combined with radiotherapy.(A) Body weight curves of LLC tumor-bearing mice over the observation period (n = 6). DTX: 4 mg/kg, PLB: 1 mg/kg, X-ray irradiation: 2.0 Gy. (B, C) Hematological and serum biochemical analyses performed after treatment (n = 6). The measured parameters included RBC, WBC, PLT, HGB, as well as liver and kidney function indices, namely ALT, AST, BUN, and CREA. (D) Representative H&E-stained sections of major organs, including heart, lung, liver, spleen, and kidney. Scale bar, 100 μm. Data are presented as mean ± SD. Body weight curves in (A) were analyzed using two-way ANOVA followed by Sidak's multiple comparisons test. Hematological and serum biochemical parameters in (B) and (C) were analyzed using a two-tailed unpaired t-test. n.s. = not significant. In vivo biosafety evaluation of (DTX + PLB)-NP combined with radiotherapy. (A) Body weight curves of LLC tumor-bearing mice over the observation period (n = 6). DTX: 4 mg/kg, PLB: 1 mg/kg, X-ray irradiation: 2.0 Gy. (B, C) Hematological and serum biochemical analyses performed after treatment (n = 6). The measured parameters included RBC, WBC, PLT, HGB, as well as liver and kidney function indices, namely ALT, AST, BUN, and CREA. (D) Representative H&E-stained sections of major organs, including heart, lung, liver, spleen, and kidney. Scale bar, 100 μm. Data are presented as mean ± SD. Body weight curves in (A) were analyzed using two-way ANOVA followed by Sidak's multiple comparisons test. Hematological and serum biochemical parameters in (B) and (C) were analyzed using a two-tailed unpaired t-test. n.s. = not significant. In conclusion, the nanoparticle formulation employs a “low-dose, high-efficacy” strategy, achieving enhanced chemoradiotherapeutic efficacy in vivo with favorable preliminary biosafety, and providing experimental support for further translational evaluation. Translational considerations and future directions Although this study demonstrated potent antitumor efficacy and favorable preliminary short-term biosafety of (DTX + PLB)-NP combined with radiotherapy, several key translational challenges must be addressed before clinical development. First, the current safety evaluation, including body weight monitoring, hematological analysis, serum biochemistry, and histological examination of major organs, should be regarded as preliminary. Future studies should perform long-term toxicity assessments under repeated dosing and clinically relevant fractionated radiotherapy schedules, with particular attention to delayed myelosuppression, hepatic and renal toxicity, cardiopulmonary toxicity, immune activation, complement activation, and histopathological changes in mononuclear phagocyte system-enriched organs. Because (DTX + PLB)-NP is a PEGylated liposomal formulation, repeated administration may induce anti-PEG IgM/IgG production, promote complement activation and mononuclear phagocyte system recognition, and thereby trigger the accelerated blood clearance phenomenon, in which subsequent doses are cleared more rapidly from the circulation. This process may shorten the circulation half-life, reduce tumor exposure, disrupt the pharmacokinetic synchronization of DTX and PLB, and increase hepatic/splenic accumulation and immune-related risks. Therefore, future studies should systematically compare pharmacokinetics, biodistribution, and immune responses after single and repeated administration, while monitoring anti-PEG antibodies, complement activation, cytokine release, and hepatic/splenic histopathological changes to evaluate the long-term safety and ABC risk of repeated PEGylated liposome administration [58]. Clinical translation also depends on standardized, scalable manufacturing and rigorous quality control. The therapeutic activity of this formulation depends not only on the co-delivery of DTX and PLB, but also on maintaining the optimized 1:1 DTX:PLB molar ratio, nanoscale particle size distribution, FA-mediated targeting capability, and synchronized release behavior. Therefore, particle size, PDI, zeta potential, DTX:PLB ratio, encapsulation efficiency, drug loading, release kinetics, FA ligand density, residual solvent, endotoxin level, sterility, and storage stability should be controlled as critical quality attributes. Scalable GMP-compatible manufacturing processes and validated release criteria will be required to ensure batch-to-batch reproducibility. For this type of combination nanomedicine, the influence of component ratio, release behavior, pharmacokinetic synchronization, and radiotherapy scheduling on efficacy and safety should also be defined to support subsequent regulatory evaluation and clinical protocol design [59,60]. In addition, as a combination nanomedicine involving two active agents, a targeting ligand, and radiotherapy, future regulatory development should clarify the contribution of each component, establish comparability criteria for manufacturing changes, and define how drug release, pharmacokinetic synchronization, and radiation scheduling will be controlled during clinical evaluation. Future development of FA-targeted nanotherapy should also incorporate patient stratification and companion diagnostic strategies. Although FA modification enhanced nanoparticle uptake and tumor accumulation in our model, FR expression in human NSCLC may vary among patients, histological subtypes, tumor sites, and intratumoral regions. Therefore, FR expression profiling by immunohistochemistry, molecular imaging, or other companion diagnostic approaches may help identify FR-positive patients who are more likely to benefit from this strategy. In early clinical studies, dose escalation should be carefully optimized in the context of fractionated radiotherapy, with close monitoring of hematological toxicity, hepatic and renal toxicity, pulmonary toxicity, and radiotherapy-related adverse events. Since our pharmacokinetic and biodistribution data showed that nanoencapsulation prolonged systemic exposure and enhanced tumor accumulation, the interval between nanoparticle administration and irradiation should be optimized to match radiotherapy with the intratumoral drug exposure window. Pharmacokinetic/pharmacodynamic modeling, γ-H2AX-associated DNA damage markers, ROS-related biomarkers, and imaging-based tumor response assessment may help guide rational scheduling. Finally, interpatient and intratumoral heterogeneity of the EPR effect remains an important translational limitation for nanomedicine. Compared with murine subcutaneous tumor models, EPR-associated accumulation in human solid tumors is often more variable and can be influenced by vascular permeability, stromal density, tumor perfusion, lymphatic drainage, interstitial fluid pressure, and tumor location. Therefore, passive accumulation alone may not ensure consistent delivery across patients. Future strategies to address EPR heterogeneity may include imaging-guided patient selection, vascular normalization, EPR-enhancing pretreatments, and integration of EPR-associated passive accumulation with FA-mediated active targeting [50,61]. For tumors with poor vascular permeability or heterogeneous FR expression, further optimization of FA ligand density, dual-ligand targeting, or locoregional delivery may improve delivery precision and therapeutic reproducibility. Addressing these issues will be essential for advancing this redox-guided liposomal chemoradiotherapy platform toward clinical translation. Conclusion In summary, we developed a redox-guided nanomedicine strategy to potentiate CCRT in NSCLC. By disrupting mitochondrial redox homeostasis, PLB functions as a critical threshold modulator, lowering the apoptotic barrier to sensitize tumor cells to DTX and ionizing radiation. To translate this synergy, our engineered folate-targeted PEGylated liposomal nanoplatform achieves the spatiotemporal synchronization of PLB and DTX at a precise 1:1 ratio. This design enhanced ROS-associated cytotoxic stress and γ-H2AX-associated DNA damage, resulting in potent antitumor effects with favorable preliminary short-term biosafety. Beyond direct cytotoxicity, the system offers a versatile translational framework for precision redox-based nanotherapy in NSCLC and other FR-overexpressing malignancies. Before clinical translation, several mechanistic hypotheses require further validation. First, FRβ expression on TAMs in the LLC tumor microenvironment should be quantitatively assessed. Second, whether (DTX + PLB)-NP alters the abundance or phenotype of CD11b+F4/80+CD206+ TAMs should be examined by flow cytometry and immunostaining. Third, FRβ-blocking strategies or FRβ-deficient models are needed to determine whether TAM-associated FRβ contributes to nanoparticle accumulation and therapeutic efficacy. Fourth, the relationship between TAM infiltration, TAM depletion or remodeling, and therapeutic response should be systematically analyzed. These studies will help clarify whether FA-mediated targeting in this system is mainly driven by tumor cell uptake or also involves stromal immune components.GlossaryAbbreviationsFull nameDTXdocetaxelCCRTconcurrent chemoradiotherapyNSCLCnon-small cell lung cancerROSreactive oxygen speciesPLBplumbaginFRfolate receptorRTradiotherapyNPnanoparticleFAfolic acidPEGpolyethylene glycolGSHglutathioneEPRenhanced permeability and retentionCLTcelastrolSNGsanguinarinDIHdihydrotanshinone IZGS IIziyuglycoside IIALTalantolactoneORIoridoninARTartesunateDMEMdulbecco's modified Eagle's mediumFBSfetal bovine serumMTT3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromideDMSOdimethyl sulfoxideBCAbicinchoninic acidECLenhanced chemiluminescenceBSAbovine serum albuminEPCegg yolk lecithinCholcholesterolDSPE-PEG-FAdisteroylphosphatidylethanolamine-poly(ethylene glycol)-folic acidDSPE-PEG20002-distearoyl-sn-glycero-3-phosphoethanolamine-N-amino(polyethylene glycol)-2000IC50half maximal (50%) inhibitory concentrationCIcombination indexMRmolar ratiosPVDFpolyvinylidene difluoridePMSFphenylmethylsulfonyl fluorideCLSMconfocal laser scanning microscopyNACN-acetyl-L-cysteineHPLChigh-performance liquid chromatographyMMPmitochondrial membrane potentialMOMPmitochondrial outer membrane permeabilizationEEencapsulation efficiencyLCloading capacityTEMtransmission electron microscopySFsurviving fractionγ-H2AXphosphorylated histone H2AXTAMtumor-associated macrophagesTIRtumor inhibition ratioH&Ehematoxylin and eosin GlossaryAbbreviationsFull nameDTXdocetaxelCCRTconcurrent chemoradiotherapyNSCLCnon-small cell lung cancerROSreactive oxygen speciesPLBplumbaginFRfolate receptorRTradiotherapyNPnanoparticleFAfolic acidPEGpolyethylene glycolGSHglutathioneEPRenhanced permeability and retentionCLTcelastrolSNGsanguinarinDIHdihydrotanshinone IZGS IIziyuglycoside IIALTalantolactoneORIoridoninARTartesunateDMEMdulbecco's modified Eagle's mediumFBSfetal bovine serumMTT3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromideDMSOdimethyl sulfoxideBCAbicinchoninic acidECLenhanced chemiluminescenceBSAbovine serum albuminEPCegg yolk lecithinCholcholesterolDSPE-PEG-FAdisteroylphosphatidylethanolamine-poly(ethylene glycol)-folic acidDSPE-PEG20002-distearoyl-sn-glycero-3-phosphoethanolamine-N-amino(polyethylene glycol)-2000IC50half maximal (50%) inhibitory concentrationCIcombination indexMRmolar ratiosPVDFpolyvinylidene difluoridePMSFphenylmethylsulfonyl fluorideCLSMconfocal laser scanning microscopyNACN-acetyl-L-cysteineHPLChigh-performance liquid chromatographyMMPmitochondrial membrane potentialMOMPmitochondrial outer membrane permeabilizationEEencapsulation efficiencyLCloading capacityTEMtransmission electron microscopySFsurviving fractionγ-H2AXphosphorylated histone H2AXTAMtumor-associated macrophagesTIRtumor inhibition ratioH&Ehematoxylin and eosin Glossary Funding This work was supported by the 10.13039/501100012166National Key Research and Development Program of China [grant number 2023YFC2411505] and the Doctor of Excellence Program of The 10.13039/501100017585First Hospital of Jilin University [grant number JDYY-DEP-2025050]. CRediT authorship contribution statement Xueying Bao: Conceptualization, Data curation, Investigation, Methodology, Software, Writing – original draft. Huanhuan Wang: Data curation, Methodology, Software, Supervision. Man Li: Data curation, Methodology, Resources, Software. Zhuangzhuang Zheng: Methodology, Resources, Software. Xuanzhong Wang: Resources, Software, Supervision, Validation. Jianfeng Guo: Conceptualization, Resources, Supervision. Xin Jiang: Conceptualization, Funding acquisition, Software, Supervision, Writing – original draft. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.